InterMune and Roche Begins Trial of Ritonavir-boosted ITMN-191 (RG7227) for Genotype 1 Chronic Hepatitis C Patients
Below is an excerpt from a recent InterMune press release describing the new study.
InterMune Announces Initiation of Ritonavir-Boosted ITMN-191/RG7227 Study in HCV Patients
Brisbane, CA -- September 29, 2009 -- InterMune, Inc. (Nasdaq: ITMN) today announced that its partner Roche has begun dosing in a Phase 1b multiple ascending dose (MAD) study of ITMN-191 (RG7227) boosted by low-dose ritonavir in patients chronically infected
with hepatitis C virus (HCV) genotype-1.
Ritonavir boosting is an option to enhance and improve pharmacokinetic profiles of protease inhibitors. It is well established in the treatment of HIV where it leads to more convenient dosing, reduced resistance development and high efficacy. Not all HCV protease inhibitors are suitable for ritonavir boosting. However, as InterMune announced on August 6, 2009, ITMN-191 showed high promise in a Phase 1 single ascending dose (SAD) study in healthy volunteers. Important PK parameters showed marked improvement and significant increases in AUC and drug concentrations were observed. There were no remarkable safety findings.
"We and our partner Roche are very pleased by the performance of ITMN-191 in twice-daily regimens when un-boosted with ritonavir," said Dan Welch, Chairman, Chief Executive Officer and President of InterMune. "However, if results of ritonavir boosting of ITMN-191 in human volunteers are replicated in this study of HCV patients, the approach could lead to achieving more sustained exposures with lower twice-daily doses of ITMN-191 or perhaps allow once-daily administration. Either of these two possibilities could provide patients a regimen with more convenient administration and with the clinical advantages associated with sustained drug exposure."
The objective of the MAD study is to determine the pharmacokinetic (PK), viral kinetic and safety profiles of ascending doses of once-daily and twice-daily ITMN-191 co-administered with low doses of ritonavir and standard dose Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) in HCV-infected patients and for 14 days. On August 6, the company announced results of a Phase 1 study of ITMN-191 co-administered with low dose ritonavir in healthy volunteers.
ITMN-191/RG7227 is a potent, macrocyclic inhibitor of HCV NS3/4A protease activity currently in Phase 2b development. The compound is being developed in collaboration with Roche. ITMN-191 has produced multi-log10 reductions in HCV levels in chronic HCV patients, when administered for 14 days as monotherapy. When ITMN-191 was combined with Pegasys and Copegus, or the NS5B polymerase in Phase 1b studies, it reduced HCV viral loads below the limit of quantification in the majority of study-treated patients. The safety and antiviral activity of ITMN-191 is also under clinical investigation in combination with the NS5B nucleoside inhibitor RG7128 in the INFORM clinical development program. To date, ITMN-191 has been safe and well tolerated in these studies.
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfenidone analog named ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as RG7227 at Roche) that entered Phase 2b in August of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.
InterMune, Inc. InterMune Announces Initiation of Ritonavir-Boosted ITMN-191/RG7227 Study in HCV Patients. Press release. September 29, 2009.